Annual CFO
-$35.82 M
-$6.63 M-22.73%
December 31, 2023
Summary
- As of February 7, 2025, RDHL annual cash flow from operations is -$35.82 million, with the most recent change of -$6.63 million (-22.73%) on December 31, 2023.
- During the last 3 years, RDHL annual CFO has risen by +$12.76 million (+26.26%).
- RDHL annual CFO is now -2094.85% below its all-time high of -$1.63 million, reached on December 31, 2010.
Performance
RDHL Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
N/A
June 1, 2024
Summary
- RDHL quarterly cash flow from operations is not available.
Performance
RDHL Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM CFO
N/A
June 1, 2024
Summary
- RDHL TTM cash flow from operations is not available.
Performance
RDHL TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
RDHL Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -22.7% | - | - |
| 3 y3 years | +26.3% | - | - |
| 5 y5 years | -3.9% | - | - |
RDHL Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -22.7% | +44.9% | ||||
| 5 y | 5-year | -22.7% | +44.9% | ||||
| alltime | all time | -2094.8% | +44.9% |
RedHill Biopharma Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2023 | -$35.82 M(+22.7%) | - | - |
| Jun 2023 | - | -$10.59 M(+47.4%) | -$26.22 M(-18.6%) |
| Mar 2023 | - | -$7.19 M(+196.8%) | -$32.22 M(+10.4%) |
| Dec 2022 | -$29.18 M(-55.1%) | -$2.42 M(-59.8%) | -$29.18 M(-29.9%) |
| Sep 2022 | - | -$6.03 M(-63.6%) | -$41.62 M(-23.8%) |
| Jun 2022 | - | -$16.58 M(+299.1%) | -$54.62 M(-4.1%) |
| Mar 2022 | - | -$4.16 M(-72.0%) | -$56.94 M(-12.5%) |
| Dec 2021 | -$65.05 M(+33.9%) | -$14.86 M(-21.9%) | -$65.05 M(+3.4%) |
| Sep 2021 | - | -$19.02 M(+0.7%) | -$62.89 M(+18.6%) |
| Jun 2021 | - | -$18.90 M(+54.0%) | -$53.04 M(+5.6%) |
| Mar 2021 | - | -$12.27 M(-3.4%) | -$50.22 M(+3.4%) |
| Dec 2020 | -$48.58 M(+19.2%) | -$12.71 M(+38.5%) | -$48.58 M(-2.3%) |
| Sep 2020 | - | -$9.17 M(-43.0%) | -$49.74 M(+0.6%) |
| Jun 2020 | - | -$16.08 M(+51.3%) | -$49.47 M(+12.8%) |
| Mar 2020 | - | -$10.62 M(-23.4%) | -$43.84 M(+7.6%) |
| Dec 2019 | -$40.75 M(+18.2%) | -$13.87 M(+55.9%) | -$40.75 M(+16.2%) |
| Sep 2019 | - | -$8.89 M(-14.9%) | -$35.07 M(+1.5%) |
| Jun 2019 | - | -$10.45 M(+38.8%) | -$34.55 M(+6.3%) |
| Mar 2019 | - | -$7.53 M(-8.1%) | -$32.50 M(-5.7%) |
| Dec 2018 | -$34.46 M(-23.0%) | -$8.19 M(-2.1%) | -$34.46 M(-14.8%) |
| Sep 2018 | - | -$8.37 M(-0.3%) | -$40.43 M(-5.1%) |
| Jun 2018 | - | -$8.40 M(-11.6%) | -$42.62 M(-3.0%) |
| Mar 2018 | - | -$9.50 M(-33.0%) | -$43.94 M(-1.8%) |
| Dec 2017 | -$44.77 M | -$14.16 M(+34.2%) | -$44.77 M(+9.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2017 | - | -$10.55 M(+8.5%) | -$40.77 M(+8.5%) |
| Jun 2017 | - | -$9.73 M(-5.8%) | -$37.59 M(+11.9%) |
| Mar 2017 | - | -$10.32 M(+1.5%) | -$33.60 M(+18.9%) |
| Dec 2016 | -$28.26 M(+58.5%) | -$10.17 M(+38.0%) | -$28.26 M(+17.2%) |
| Sep 2016 | - | -$7.37 M(+28.5%) | -$24.12 M(+17.7%) |
| Jun 2016 | - | -$5.74 M(+15.2%) | -$20.49 M(+5.4%) |
| Mar 2016 | - | -$4.98 M(-17.4%) | -$19.43 M(+9.0%) |
| Dec 2015 | -$17.83 M(+45.8%) | -$6.03 M(+60.9%) | -$17.83 M(+0.5%) |
| Sep 2015 | - | -$3.75 M(-20.0%) | -$17.73 M(-0.3%) |
| Jun 2015 | - | -$4.68 M(+38.8%) | -$17.79 M(+3.0%) |
| Mar 2015 | - | -$3.37 M(-43.2%) | -$17.28 M(+41.3%) |
| Dec 2014 | -$12.23 M(+45.0%) | -$5.94 M(+56.1%) | -$12.23 M(+39.8%) |
| Sep 2014 | - | -$3.80 M(-8.6%) | -$8.75 M(+24.1%) |
| Jun 2014 | - | -$4.16 M(-348.4%) | -$7.05 M(+40.9%) |
| Mar 2014 | - | $1.68 M(-168.3%) | -$5.00 M(-40.7%) |
| Dec 2013 | -$8.44 M(+24.2%) | -$2.45 M(+16.5%) | -$8.44 M(+12.1%) |
| Sep 2013 | - | -$2.11 M(-0.6%) | -$7.53 M(+9.3%) |
| Jun 2013 | - | -$2.12 M(+20.5%) | -$6.88 M(+5.6%) |
| Mar 2013 | - | -$1.76 M(+13.7%) | -$6.52 M(-4.1%) |
| Dec 2012 | -$6.79 M(+44.9%) | -$1.55 M(+5.7%) | -$6.79 M(+29.5%) |
| Sep 2012 | - | -$1.46 M(-16.4%) | -$5.25 M(+38.6%) |
| Jun 2012 | - | -$1.75 M(-14.0%) | -$3.79 M(+86.0%) |
| Mar 2012 | - | -$2.04 M | -$2.04 M |
| Dec 2011 | -$4.69 M(+187.4%) | - | - |
| Dec 2010 | -$1.63 M | - | - |
FAQ
- What is RedHill Biopharma annual cash flow from operations?
- What is the all time high annual CFO for RedHill Biopharma?
- What is RedHill Biopharma annual CFO year-on-year change?
- What is the all time high quarterly CFO for RedHill Biopharma?
- What is the all time high TTM CFO for RedHill Biopharma?
What is RedHill Biopharma annual cash flow from operations?
The current annual CFO of RDHL is -$35.82 M
What is the all time high annual CFO for RedHill Biopharma?
RedHill Biopharma all-time high annual cash flow from operations is -$1.63 M
What is RedHill Biopharma annual CFO year-on-year change?
Over the past year, RDHL annual cash flow from operations has changed by -$6.63 M (-22.73%)
What is the all time high quarterly CFO for RedHill Biopharma?
RedHill Biopharma all-time high quarterly cash flow from operations is $1.68 M
What is the all time high TTM CFO for RedHill Biopharma?
RedHill Biopharma all-time high TTM cash flow from operations is -$2.04 M